drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR T)
drug_description
Autologous second-generation anti-CD19 chimeric antigen receptor T-cell therapy using an HI19α-derived scFv with 4-1BB and CD3ζ signaling domains to target and eliminate CD19+ B cells/plasmablasts, aiming to reduce pathogenic autoantibody production in AIHA/Evans syndrome.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Gene therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an anti‑CD19 chimeric antigen receptor (HI19a-derived scFv with 4-1BB costimulatory and CD3zeta signaling domains). Binding to CD19 on B cells and plasmablasts activates the CAR T cells, leading to expansion and cytotoxic elimination of CD19+ cells, thereby depleting pathogenic B-cell populations and reducing autoantibody production in AIHA/Evans syndrome.
drug_name
CNCT19 CAR-T cell therapy
nct_id_drug_ref
NCT06231368